In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enzytech Inc.

Division of Alkermes PLC

Latest From Enzytech Inc.

Microcide-Althexis: Merge to License

Big Pharma in-licensing has been kind to anti-infectives start-ups Cubist and Versicor, giving them near-term products and significant valuations. Now Althexis, hoping to capitalize on similar opportunities, is merging with Microcide. The deal is a way of jumpstarting the still nascent Althexis and re-starting Microcide, re-setting its valuation and development clock. With Microcide's cephalosporin, technology-based Althexis would get the product focus it lacked. And the deal comes with $60mm in new money from investors who've bought CEO Mark Skaletsky's vision and want him to repeat his success at GelTex.
BioPharmaceutical Business Strategies

Drug Delivery Start-Ups

As an industry segment, drug delivery was virtually created by two companies--Alza Corp. and Elan Corp. PLC. These companies have since evolved into drug companies, abandoning a significant part of the field to second-generation arrivistes. Such companies that have survived the funding drought for small-cap companies have benefited, Inhale Therapeutics, for example, has a number of partnerships for its pulmonary delivery technology. Alkermes, probably the leading drug-delivery pure play, now has its first approved product. What is somewhat surprising about the industry is how little it has consolidated, particularly when one considers that no single drug delivery technology is applicable to a majority of drug delivery problems.
BioPharmaceutical Business Strategies

Where Biotech CEOs Come From

Many of the CEOs that took biotech firms public from 1995-96 have deep roots in the biotech industry. Unlike previous waves of CEOs, these execs are prized more for marketing shares than drugs.
BioPharmaceutical Leadership
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alkermes PLC
  • Senior Management
  • Robert Breyer, Pres. & CEO
    Robert Morgan, CFO
    Howard Bernstein, MD, PhD, VP, Research
  • Contact Info
  • Enzytech Inc.
    Phone: (617) 252-0001
    64 Sidney St.
    Cambridge, MA 02139-4136
    USA
UsernamePublicRestriction

Register